Latteyer S, Klein-Hitpass L, Khandanpour C, Zwanziger D, Poeppel T D, Schmid K W, Führer D, Moeller L C
Department of Endocrinology and Metabolism (S.L., C.K., D.Z., D.F., L.C.M.), Institute of Cell Biology (Cancer Research) Faculty of Medicine (L.K.-H.), Department of Hematology (C.K.), Department of Nuclear Medicine (T.D.P.), and Institute of Pathology (K.W.S.), University of Duisburg-Essen, 45141 Essen, Germany.
J Clin Endocrinol Metab. 2016 Mar;101(3):1016-22. doi: 10.1210/jc.2015-2948. Epub 2016 Jan 14.
Multiple endocrine neoplasia type 2 (MEN2) is usually caused by missense mutations in the proto-oncogene, RET.
This study aimed to determine the mutation underlying MEN2A in a female patient diagnosed with bilateral pheochromocytoma at age 31 years and with medullary thyroid carcinoma (MTC) 6 years later.
Leukocyte DNA was used for exome and Sanger sequencing. Wild-type (WT) RET and mutants were expressed in HEK293 cells. Activation of MAPK/ERK and PI3K/AKT was analyzed by Western blotting and luciferase assay. The effect of RET mutants on cell proliferation was tested in a colony forming assay.
Exome sequencing revealed a 6-nucleotide/2-amino acid in-frame deletion in exon 7 of RET (c.1512_1517delGGAGGG, p.505_506del). In vitro expression showed that phosphorylation of the crucial tyrosine 905 was much stronger in the p.505_506del RET mutant compared with WT RET, indicating ligand-independent autophosphorylation. Furthermore, the p.505_506del RET mutant induced a strong activation of the MAPK/ERK pathway and the PI3K/AKT pathway. Consequently, the p.505_506del RET mutant cells increased HEK293 colony formation 4-fold compared with WT RET.
The finding of bilateral pheochromocytoma and MTC in our patient was highly suspicious of a RET mutation. Exome sequencing revealed a 6-base-pair deletion in exon 7 of RET, an exon not yet associated with MEN2. Increased ligand-independent phosphorylation of the p.505_506del RET mutant, increased activation of downstream pathways, and stimulation of cell proliferation demonstrated the pathogenic nature of the mutation. We therefore recommend screening the whole sequence of RET in MTC and pheochromocytoma patients with red flags for a genetic cause.
2型多发性内分泌腺瘤病(MEN2)通常由原癌基因RET中的错义突变引起。
本研究旨在确定一名31岁诊断为双侧嗜铬细胞瘤、6年后发生甲状腺髓样癌(MTC)的女性患者中MEN2A的潜在突变。
使用白细胞DNA进行外显子组测序和桑格测序。野生型(WT)RET和突变体在HEK293细胞中表达。通过蛋白质免疫印迹和荧光素酶测定分析MAPK/ERK和PI3K/AKT的激活情况。在集落形成试验中测试RET突变体对细胞增殖的影响。
外显子组测序显示RET外显子7中有一个6核苷酸/2氨基酸的框内缺失(c.1512_1517delGGAGGG,p.505_506del)。体外表达显示,与WT RET相比,p.505_506del RET突变体中关键酪氨酸905的磷酸化要强得多,表明存在非配体依赖性自磷酸化。此外,p.505_506del RET突变体诱导MAPK/ERK途径和PI3K/AKT途径的强烈激活。因此,与WT RET相比,p.505_506del RET突变体细胞使HEK293集落形成增加了4倍。
我们的患者中双侧嗜铬细胞瘤和MTC的发现高度怀疑存在RET突变。外显子组测序显示RET外显子7中有一个6碱基对缺失,该外显子尚未与MEN2相关联。p.505_506del RET突变体非配体依赖性磷酸化增加、下游途径激活增加以及细胞增殖受刺激,证明了该突变的致病性。因此,我们建议对有遗传病因警示信号的MTC和嗜铬细胞瘤患者筛查RET的全序列。